Abstract:Background The evidence of the association between warfarin and risk of mortality compared with direct oral anticoagulants (DOACs) has been mixed in current literature. Purpose To investigate the association between all-cause mortality and warfarin, compared with DOACs. Methods Population-based cohort studies were conducted using the data from the Hong Kong Clinical Data Analysis and Reporting System (CDARS) and United Kingdom Clinical Practice Research Datalink (CPRD) Aurum. People with atrial fibrillation aged ≥18 years who initiated warfarin or a DOAC during the study period (1st Jan 2014 - 31st Dec 2019) were identified. Follow-up started from the first date of oral anticoagulant prescription and ended at earliest of the date of death, the day before drug switching (between warfarin and DOACs), transferring out of the practice (CPRD Aurum only), last data collection date for the practice (CPRD Aurum only) or the end of study period. We estimated propensity score (PS) based on the list of potential confounders including demographics, co-morbidities, co-medications and polypharmacy. Cox proportional hazards regression model with PS-weighting was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Results Among 227,190 new oral anticoagulant users, 54,367 (23.93%) died. The median follow-up was 2.96 and 2.45 years in CPRD and CDARS, respectively. Compared with DOAC use, a lower hazard of all-cause mortality was found in warfarin use (PS-weighted hazard ratio [HR]=0.94, 95% confidence interval [CI]=0.89-0.99) in CPRD; while a higher hazard was observed in warfarin users (PS-weighted HR=1.31, 95% CI=1.24-1.39) in CDARS, versus DOAC users. Consistent results were seen in both databases when stratified warfarin users by Time in Therapeutic Range (TTR). We observed a lower hazard of all-cause mortality in warfarin users with TTR≥65% (PS-weighted HR=0.90, 95% CI=0.85-0.94 in CPRD; 0.87, 0.79-0.96 in CDARS) and increased hazard in warfarin users with TTR<65% (PS-weighted HR=1.37, 95% CI=1.25-1.49 in CPRD; 1.57, 1.48-1.66 in CDARS), versus DOAC users. Conclusions The hazard of all-cause mortality associated with warfarin compared with DOACs were found to be conflicting across databases. However, both databases consistently showed that an increased hazard of all-cause mortality was only found in warfarin users with TTR<65% but not in those with TTR≥65%, suggesting that the differences in hazard of all-cause mortality associated with warfarin compared with DOAC, in part may depend on anticoagulation control in warfarin users. We recommend that warfarin users with poor INR control warrant closer clinical attention and could be considered for a switch to DOACs.

Risk of hospitalization for upper gastrointestinal bleeding in Helicobacter pylori eradicated patients newly started on warfarin or direct oral anticoagulants: A population‐based cohort study

Long‐term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication: a population‐based cohort study

Divergent trends of hospitalizations for upper and lower gastrointestinal bleeding based on population prescriptions of aspirin, proton pump inhibitors and Helicobacter pylori eradication therapy

Benefit and Harm of Aspirin on Mortality From Gastrointestinal Cancers Vs Bleeding in Helicobacter pylori-Eradicated Patients

Safety and Effectiveness of Direct Oral Anticoagulants vs. Warfarin in Patients With Atrial Fibrillation and Endoscopy-Diagnosed Peptic Ulcer

Reduction of upper gastrointestinal bleeding risk with proton pump inhibitor therapy in Asian patients with atrial fibrillation receiving direct oral anticoagulant: A nationwide population-based cohort study

Delay in Retreatment of Helicobacter pylori Infection Increases Risk of Upper Gastrointestinal Bleeding

Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low-dose rivaroxaban, or the combination: Secondary analysis of the COMPASS randomised controlled trial

Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users.

[Retrospective analysis of correlative factors between digestive system injury and anticoagulant or antiplatelet-agents]

Preventing Recurrent Upper Gastrointestinal Bleeding in Patients with Helicobacter Pylori Infection Who Are Taking Low-Dose Aspirin or Naproxen

Prospective Randomized Trial of H-Pylori Eradication Versus Maintenance Omeprazole to Prevent Recurrent Upper Gastrointestinal Hemorrhage in High-Risk Aspirin and Non-Aspirin Nsaid Users.

Association between warfarin and direct oral anticoagulants users and risk of mortality: cohort studies in England and Hong Kong

IDDF2018-ABS-0209 Venous Thromboembolism in Patients with Inflammatory Bowel Disease in China: Investigations into Incidence and Risk Factors

Incidence and Related Factors of Upper Gastrointestinal Bleeding in a Chinese Population of Peripheral Arterial Disease During a Six-Year Follow-Up.

Similar Efficacy of Proton-Pump Inhibitors Vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin

Comparison of Prophylactic Effect of UGIB and Effects on Platelet Function Between PPIs and H2RAs Combined with DAPT: Systematic Review and Meta-Analysis.

Does Eradication of Helicobacter Pylori Impair Healing of Nonsteroidal Anti-Inflammatory Drug Associated Bleeding Peptic Ulcers? A Prospective Randomized Study.

Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-Blind, Randomised Trial.

Risk factors for upper gastrointestinal bleeding among aspirin users: An old issue with new findings from a population-based cohort study

Association of direct oral anticoagulant-proton pump inhibitor cotherapy with adverse outcomes: protocol for a population-based cohort study